WO2003053458A1 - Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético - Google Patents
Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético Download PDFInfo
- Publication number
- WO2003053458A1 WO2003053458A1 PCT/CU2002/000011 CU0200011W WO03053458A1 WO 2003053458 A1 WO2003053458 A1 WO 2003053458A1 CU 0200011 W CU0200011 W CU 0200011W WO 03053458 A1 WO03053458 A1 WO 03053458A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- egf
- pharmaceutical composition
- previous
- composition containing
- treatment
- Prior art date
Links
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title claims abstract description 54
- 238000002266 amputation Methods 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 208000008960 Diabetic foot Diseases 0.000 title abstract description 14
- 230000002265 prevention Effects 0.000 title description 3
- 230000003902 lesion Effects 0.000 claims abstract description 41
- 230000008595 infiltration Effects 0.000 claims abstract description 40
- 238000001764 infiltration Methods 0.000 claims abstract description 40
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 230000010410 reperfusion Effects 0.000 claims abstract description 9
- 230000007654 ischemic lesion Effects 0.000 claims abstract description 6
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 48
- 229940116977 epidermal growth factor Drugs 0.000 claims description 47
- 230000000302 ischemic effect Effects 0.000 claims description 27
- 206010012601 diabetes mellitus Diseases 0.000 claims description 17
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 5
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 claims description 5
- 210000003141 lower extremity Anatomy 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 2
- 208000037906 ischaemic injury Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 32
- 229930013032 isoflavonoid Natural products 0.000 claims 3
- 150000003817 isoflavonoid derivatives Chemical class 0.000 claims 3
- 235000012891 isoflavonoids Nutrition 0.000 claims 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims 1
- 229960001456 adenosine triphosphate Drugs 0.000 claims 1
- 239000012062 aqueous buffer Substances 0.000 claims 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims 1
- 235000005493 rutin Nutrition 0.000 claims 1
- 229960004555 rutoside Drugs 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 abstract description 10
- 208000025865 Ulcer Diseases 0.000 abstract description 9
- 230000001684 chronic effect Effects 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 238000001356 surgical procedure Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 231100000397 ulcer Toxicity 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 4
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract description 2
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 230000035899 viability Effects 0.000 abstract description 2
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001926 lymphatic effect Effects 0.000 abstract 1
- 238000002278 reconstructive surgery Methods 0.000 abstract 1
- 230000035876 healing Effects 0.000 description 17
- 102400001368 Epidermal growth factor Human genes 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 12
- 206010063560 Excessive granulation tissue Diseases 0.000 description 11
- 210000001126 granulation tissue Anatomy 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000002458 infectious effect Effects 0.000 description 10
- 210000003414 extremity Anatomy 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 6
- 108010081589 Becaplermin Proteins 0.000 description 5
- 206010011703 Cyanosis Diseases 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002981 neuropathic effect Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000035901 Ischaemic ulcer Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000006735 Periostitis Diseases 0.000 description 3
- 206010034576 Peripheral ischaemia Diseases 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000000459 calcaneus Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003460 periosteum Anatomy 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 206010050502 Neuropathic ulcer Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 1
- 229960004787 becaplermin Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002425 cardiocirculatory effect Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000010060 microvascular dysfunction Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000005122 simple epithelium Anatomy 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the use of a pharmaceutical composition containing Epidermal Growth Factor (EGF), preferably for injection and to be administered by infiltration into and around chronic ischemic skin lesions, for the prevention of diabetic foot amputation. . It can also be administered on newly created surgical surfaces and damaged by the effect of acute reperfusion with oxygenated blood after prolonged ischemia. This prevents surgical reinterventions and promotes limb preservation.
- EGF Epidermal Growth Factor
- metabolic correction which is based on the general control of risk factors and functional rest of the affected area.
- Another commonly used procedure is the use of antibiotics and early debridement of the fistulized pathways. It is performed whatever the perfusion situation of the infected foot.
- Hemorrheological Therapy which is based on the prevalence shown in the diabetic patient of hemorrhagic disorders and their role in the infection.
- Vasoactive therapy which has been used in local perfusion disorders, both due to macro and microangiopathy, with certain prostanoids acting at the tissue level.
- the patient's cardiocirculatory, renal and hepatic functions must be previously assessed, taking into account the frequent involvement of the first two in diabetic patients. They have also been used for certain states, platelet antiaggregants, and thrombolytic agents.
- the revascularization technique in the diabetic or non-diabetic ischemic patient is risky, expensive and not applicable to all patients, being its very limited indication, as well as endovascular surgery, which has shown viability limitations, both in the arterial sectors Aorto-ll ⁇ aco as Femoro-Popl ⁇ teo, attributable to calcification and greater lesional sectoriality.
- Lumbar sympathectomy is today exceptionally practiced in diabetic patients. The existence of a more or less evolved autonomic neuropathy makes it ineffective. Recently, the US Federal Food and Drug Administration (FDA) approved the use of human recombinant platelet-derived growth factor (PDGF) to stimulate the healing of neuropathic ulcers of the diabetic foot.
- FDA Federal Food and Drug Administration
- PDGF platelet-derived growth factor
- the results of the most recent, double-blind, multi- centric and randomized clinical trial show only 50% efficacy (T. Jeffery Wieman, Janice M. Smiell, Yachin Su. Efficacy and safety of topical gel formulation of recombinant human platelet-derived growth factor -BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998, 21: 822-827).
- the lesions treated in the trial with the recombinant PDGF-BB are incomparable in relation to the type and magnitude of which we have managed to heal with our invention.
- the test is performed on neuropathic lesions with a normal supply of arterial blood.
- the treated lesions are classifiable as grades IV - V of the Wagner scale with a severe ischemic component.
- All lesions included in our treatment scheme included a size greater than 20 square centimeters and from 10 to 40 millimeters deep.
- a critical aspect is the high recurrence rate reported in the PDGF-BB trial, being 30% in three months.
- Another recent invention for the treatment of extensive acute skin lesions such as burns, or chronic such as venous ulcers has been the creation of equivalent substitutes for human bioartificial skin. There are no controlled clinical studies in ischemic ulcers of the diabetic foot, and it is unlikely that these products can control the underlying ischemic process as a cause of healing failure (Editorial. New Skin for O ⁇ d. Developments in Biological Skin Substitutes. Arch Dermatol 1998; 134: 344-348).
- the object of this invention is the use of an injectable pharmaceutical composition containing Epidermal Growth Factor (EGF), which is capable of stimulating tissue survival and adaptation to hypoxia;
- EGF Epidermal Growth Factor
- the composition also allows irreversible healing of chronic skin lesions, of an ulcerative nature or not, classifiable as ischemic, or of those wounds damaged by the effect of reperfusion with arterial blood on the skin and adjacent soft tissues.
- ischemic injury is defined as those that occur in the skin and soft parts of the lower extremities of the diabetic patient, as a result of a pre-existing failure of peripheral perfusion due to damage to large and small vessels.
- the composition of the invention has been shown to start and maintain in a stable and irreversible way the healing process of chronic skin ulcers refractory to existing treatments, preventing the practice of amputations when there is no other alternative for the ischemic limb. It is particularly useful for preventing damage associated with surgical reperfusion, so that it is possible to control the atony and devitalization of tissues, to the point that it is unnecessary to continue removing areas of the limb.
- the composition by An initial mechanism of cytoprotection and rescue allows the healing of ischemic / infectious and neuropathic diabetic foot ulcers.
- the composition of the invention is used by local infiltration. This means the direct instillation of the composition in deep areas of the edges and the bottom of the lesions.
- the administration is carried out in the form of a block by inserting the needle at different points of the lesion, more or less equidistant and covering the entire deep surface of the fundus and contours of the lesions. Administration must be done by depositing the composition between 4 and 20 local infiltration points, and there must be a distance of 1 to 1.5 centimeters between the points.
- the number of points to be covered is at the discretion of the specialist who performs the infiltrations. Obviously, extensive and deep lesions are going to demand a greater number of instillation points.
- the specialist must perceive two effects at the time of administration: local edema and resistance of the tissue to the entry of the composition.
- the performance of practices such as resuscitation of edges and bottom of the wound will be at the discretion of the specialist; These practices are often significantly reduced as the treatment progresses. If at some point atony of the edges of the epithelium can be seen when a mature granulation tissue already exists, the epithelium can be conservatively resuscitated, and then proceed to infiltrate the sub-epithelial position.
- infiltration has been used as a treatment scheme on alternate days in a week, so that three infiltration sessions are held every week. The number of infiltration points in each session depends on the size of the lesion, but ranges from 4-20.
- ischemic / infectious lesions classifiable as grade IV and V of the Wagner scale the onset of granulation tissue outbreak is observed from the sixth session of infiltrations. In less severe lesions, it is possible to observe the beginning of response from the first week of treatment, that is, after three infiltration sessions. Alternatively, in cases of very severe ischemia with total absence of pulses, and patients with anemia below 9 g / l of hemoglobin, the treatment has been applied daily. In these patients, evidence of granulation begins at the ninth infiltration session.
- the composition may contain the EGF polypeptide, obtained naturally, by chemical synthesis, or by recombinant DNA technology. With the use of the pharmaceutical composition containing EGF of the present invention it has been possible to regenerate tissue in chronic and ischemic lesions, being little invasive, and capable of reducing the number of surgical interventions and amputations.
- the use of the present composition has allowed (I) the elimination of ischemic capsules or scabs without the need for surgical procedures. This is related to the formation of new remodeling tissue in the deep planes, which pushes and releases the necrotic material. (II) The establishment of a neoformation tissue, fibroangiogenic, intracutaneous, resulting from successive infiltrations, before performing an amputation, for example of fingers, which causes a pro-granulating tissue to exist before the surgical act itself, which limits sepsis, promotes healing and mitigates the risks of reperfusion if necessary.
- the components of the pharmaceutical composition are the following:
- EGF Epidermal Growth Factor
- the EGF can be in powder or fine granulated form and can be applied by means of a high pressure firing device. EGF can be administered in the form of deoxyribonucleic acid (DNA) in an appropriate genetic construct for expression in transiently transfected human cells.
- DNA deoxyribonucleic acid
- PEI Polyethyleneimine
- Sodium Phosphate buffer Chemical stabilizer It is at a pH of 6.5 and in a molar concentration range between 5-100 milliMolar (mM), and at an optimal range of 10-20 milliMolar (mM).
- O-Raffinose Stabilizing agent in the lyophilization process. Concentrations of 5-50 milligrams / milliliter, and at an optimal range of 8-20 milligrams / milliliter can be used.
- L-Glycine L-Glycine. Isotonizing agent It can be used at concentrations of 5-50 milligrams / milliliter, and at an optimal range of 10-20 milligrams / milliliter.
- Fibronectin It favors the stability of EGF and its biological function. It favors the interaction of EGF with cells and their response. It is present in the formulation in ranges from 10 to 200 micrograms / ml.
- Levana EGF protective agent in solution exerts screen effect. It contributes to its biodistribution in the extracellular space. It is present in the formulation in ranges from 1 to 20 milligrams / ml.
- the pharmaceutical composition can also combine EGF with the following active ingredients:
- Phlebotonic and phlebotrophic It may be present in the formulation in concentrations of 20 micrograms / ml to 1000 micrograms / ml. Use it as a simple routine hydrate or in the form of lyophilized salt in the form of routine sulfate.
- Lidocaine Trophic It helps reduce the local production of pro-inflammatory cytokines and the expression of adhesion molecules of the vascular wall.
- lidocaine hydrochloride Present in the form of lidocaine hydrochloride and can be at a fluctuating concentration between 5 to 40 milligrams / ml.
- Adenosine triphosphate (ATP) It exerts vasodilator and pro-metabolic effect.
- It may be present in the form of sodium salt or free acid, at a fluctuating concentration between 0.05 to 20 milligrams / ml.
- GTP Guanosine triphosphate
- Nictinic acid amide (Nictoinamide). Provides substrates for cell anabolic. It can be used at a fluctuating concentration between 1 to 130 milligrams / ml. L-Arginine It favors the regulation of vascular tone. It is used in the form of hydrochloride crystals, being able to be at a fluctuating concentration between 1 to 100 nanograms / ml.
- Heparin Cytoprotector Use it in the form of sodium salt, being able to be at a fluctuating concentration between 1 to 10 micrograms / ml (0.1-1 U).
- Type II diabetes mellitus with evolution from 10 to 25 years, mostly medicated with oral hypoglycemic agents.
- All lesions of the lower limbs treated corresponded with the clinical-pathological classification of ischemic / infectious diabetic foot or ischemic / neuropathic diabetic foot or mixed forms. Grades IV or V of the Wagner classification.
- the treatment consisted of performing deep perilesional infiltrations in at least five or six equidistant points at the edges of the lesion, always directing the needle towards the base of the ulcer or deep into the surgical wedge. At each point a volume of 1 milliliter (mi) of the composition was deposited. No undesirable reactions were detected except pain from injection.
- the composition administered always contained EGF as the main active ingredient, in some cases it was tested in combination with any of the aforementioned active ingredients. In the 9 treated patients the amputation of fingers, foot, or limb as appropriate. The total number of infiltration sessions that each patient received is referred to in the examples.
- Example 1 ACDF patient, 49 years of age and female sex. Patient with infectious ischemic foot, type II diabetes with 16 years of evolution, who had undergone sympathectomy and supracondylar amputation of the right limb 2 1/2 years ago. The first toe of the left foot is amputated for showing an ulcerative, moist, atonic lesion, rebel to heal despite the fact that several surgical cures were performed to remove ischemic capsules, practice debridement and revitalize the edges and bottom of the lesion. The basis of the amputation became ischemic, with cyanotic and atonic edges 5 days after the intervention. The treatment of the infiltrations is begun, waiting for the spontaneous epithelization of the lesion.
- an ischemic capsule is implanted in the surgical area and the base of the adjacent finger.
- the lesion becomes atonic and the progress of healing stops.
- the fingers are disarticulated and open a latero-inferior wedge that was transformed into a tunnel of approximately 6 cm. of length.
- the lesion became again ischemic and with evidence of necrosis of some areas of the edges.
- the treatment with the infiltrations begins with the expectation of healing by second intention.
- the lesion had healed completely, covered with a well-keratinized epithelium, " discharging from the hospital. Remodeling of the lesion was observed.
- Example 4. RNP patient, 69 years old, male sex.
- the evidence of improvement began at the sixth infiltration session, the pain disappearing and the outbreaks of granulation tissue begin from the bottom of the bloody area: after 12 infiltration sessions the patient had completely epithelized; that is to say at 4 weeks of treatment. He was discharged from hospital. It has evolved satisfactorily without recurrences for a period of three months.
- Example 5 ISV patient, 74, female sex. Diabetic for 30 years. With an infectious ischemic diabetic foot. Contralateral transmetatarsal amputation. History of deficit in the healing process. Enter for maintaining a necrotic lesion of the fifth finger. It is amputated and ischemic plaques appear that are surgically removed. Finally it is left with a wedge of the infero-outer edge of the foot, with exposed periosteum. At 48 hours the wedge showed signs of ischemia. It is decided to start treatment with the infiltrations hoping to fill the lesion, including the wedge with granulation tissue; that is, a spontaneous scarring by second intention. At the end of the sixth infiltration, there was already an outbreak of useful and bleeding granulation tissue.
- the lesion responded favorably to treatment resulting in epithelized after 11 sessions. It has evolved satisfactorily after hospital discharge.
- Example 6 RDR patient, 44 years old, male. Diabetic for 12 years. Carrier of an infectious ischemic diabetic foot who receives transmetatarsal amputation due to ischemic lesions of the fingers. Lacking distal pulses, and clinical evidence of peripheral perfusion insufficiency. History of failed healing process in the contralateral tibial region. After the amputation is performed, cyanotic foci appear on the skin's edges. The infiltration begins with the expectation of creating granulation tissue to support an autograft or to reshape and heal by second intention.
- Example 7 Patient RGR. Female sex, 49 years old. Diabetic patient about 10 years ago, with a history of painful claudication at 100 meters, and scarring deficit. He has detoured with several ulcers in the para-tibial region of both members, which have been difflious to treatment.
- the lesion that is decided to treat is an ischemic ulcer in the lower third of the left leg, on its outer lateral face, approximately 6.4 centimeters in diameter and 5 millimeters deep, with a two-month evolution without response. Initially a resuscitation of edges and bottom was performed, beginning the treatment with infiltrations the next day. The lesion began to show granular background at the third infiltration, progressed with contraction of the edges and proliferation of a simple epithelium that then stratified and keratinized. A total of 12 infiltration sessions (4 weeks of treatment) were performed. After hospital discharge, it has evolved satisfactorily.
- Example 8 GPJ patient. 57 years old Diabetic from 12 years ago. Carrier of an infectious ischemic foot, and lacking posterior tibial pulse. A transmetatarsal amputation is performed due to ischemia and four-finger necrosis of the right limb. Seven days after the amputation, the healing process in the surgical base is stopped, areas of the cutaneous edges are cyanotic and devitalized. Infiltrative treatment is tested before continuing with surgical interventions. After 9 sessions (3 weeks) on patient had completely epithelized. After hospital discharge, it has evolved without complications.
- Example 9 DLF patient. 51 years old, male. Type II diabetic for about 20 years and asthmatic. It is received with a bad plantar perforator with no other option than amputation due to the severe degree of local ischemic and necrotic involvement. There was almost total loss of the left foot plant. The calcaneus area culminates with exposed periosteum. It is treated with infiltrations as a pre-amputation alternative. The only expected possibility was the presence of a granulation tissue sufficiently established and vascularized to support an autograft. 15 infiltration sessions were conducted throughout the area including the calcaneus. From the fifth administration, the tissue outbreak began to be appreciated. After the 15 infiltration sessions (5 weeks), the autograft could be performed. The patient has evolved satisfactorily, is supported and wanders.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HK05109793A HK1077740A1 (en) | 2001-12-20 | 2001-12-04 | Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation |
CA2470971A CA2470971C (en) | 2001-12-20 | 2002-12-04 | Use of pharmaceutical composition containing epidermal growth factor (egf) for preventing diabetic limb amputation |
JP2003554215A JP4808378B2 (ja) | 2001-12-20 | 2002-12-04 | 上皮増殖因子(egf)を包含する医薬組成物を用いた、糖尿病における下肢切断の予防方法 |
BRPI0215214A BRPI0215214B8 (pt) | 2001-12-20 | 2002-12-04 | uso do fator de crescimento epidérmico, e, composição farmacêutica |
US10/499,457 US7465704B2 (en) | 2001-12-20 | 2002-12-04 | Methods for enhancing healing of diabetic foot ulcers by injecting epidermal growth factor (EGF) |
ES02796491T ES2322568T3 (es) | 2001-12-20 | 2002-12-04 | Uso de una composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. |
UA20040705897A UA80813C2 (en) | 2001-12-20 | 2002-12-04 | Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation |
DE60231248T DE60231248D1 (de) | 2001-12-20 | 2002-12-04 | Verwendung einer epidermalen wachstumsfaktor (egf) enthaltenden pharmazeutischen zusammensetzung zur vermeidung einer fussamputation bei diabetes |
EP02796491A EP1466617B1 (en) | 2001-12-20 | 2002-12-04 | Use of a pharmaceutical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention |
DK02796491T DK1466617T3 (da) | 2001-12-20 | 2002-12-04 | Anvendelse af en farmaceutisk sammensætning indeholdende epidermal vækstfaktor (EGF) til forebyggelse af diabetisk fodamputation |
SI200230818T SI1466617T1 (sl) | 2001-12-20 | 2002-12-04 | Uporaba farmacevtskega sestavka, ki vsebuje epidermalni rastni faktor (EGF), za preprečevanje amputacije diabetičnega stopala |
AU2002361923A AU2002361923B2 (en) | 2001-12-20 | 2002-12-04 | Use of a pharmaceutical composition containing Epidermal Growth Factor (EGF) for diabetic foot amputation prevention |
MXPA04005831A MXPA04005831A (es) | 2001-12-20 | 2002-12-04 | Uso de una composicion farmaceutica que contiene factor de crecimiento epidermico (egf) para prevencion de amputacion del pie diabetico. |
CNB02828268XA CN1306954C (zh) | 2001-12-20 | 2002-12-04 | 表皮生长因子在制备预防糖尿病肢端坏疽截肢的注射用药物组合物中的用途 |
KR1020047009772A KR100795654B1 (ko) | 2001-12-20 | 2002-12-04 | 당뇨성 발 절단 예방을 위한 표피성장인자 함유 약제학적조성물의 용도 |
ZA2004/05612A ZA200405612B (en) | 2001-12-20 | 2004-07-14 | Use of a pharmaceutical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention |
US12/197,001 US7799760B2 (en) | 2001-12-20 | 2008-08-22 | Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU0308/01 | 2001-12-20 | ||
CU20010308A CU23043A1 (es) | 2001-12-20 | 2001-12-20 | Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10499457 A-371-Of-International | 2002-12-04 | ||
US12/197,001 Continuation US7799760B2 (en) | 2001-12-20 | 2008-08-22 | Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003053458A1 true WO2003053458A1 (es) | 2003-07-03 |
Family
ID=40239814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2002/000011 WO2003053458A1 (es) | 2001-12-20 | 2002-12-04 | Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético |
Country Status (22)
Country | Link |
---|---|
US (2) | US7465704B2 (es) |
EP (1) | EP1466617B1 (es) |
JP (1) | JP4808378B2 (es) |
KR (1) | KR100795654B1 (es) |
CN (1) | CN1306954C (es) |
AR (1) | AR037824A1 (es) |
AT (1) | ATE422897T1 (es) |
AU (1) | AU2002361923B2 (es) |
BR (1) | BRPI0215214B8 (es) |
CA (1) | CA2470971C (es) |
CU (1) | CU23043A1 (es) |
DE (1) | DE60231248D1 (es) |
DK (1) | DK1466617T3 (es) |
ES (1) | ES2322568T3 (es) |
HK (1) | HK1077740A1 (es) |
MX (1) | MXPA04005831A (es) |
MY (1) | MY139214A (es) |
PT (1) | PT1466617E (es) |
RU (1) | RU2289424C2 (es) |
SI (1) | SI1466617T1 (es) |
UA (1) | UA80813C2 (es) |
WO (1) | WO2003053458A1 (es) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007073704A1 (es) | 2005-12-29 | 2007-07-05 | Centro De Ingeniería Genética Y Biotecnología | Uso tópico del factor de crecimiento epidermico en liposomas para prevenir la amputacion del pie diabético |
WO2007087759A2 (es) | 2006-01-31 | 2007-08-09 | Centro De Ingeniería Genética Y Biotecnología | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
WO2010000904A1 (es) | 2008-07-01 | 2010-01-07 | Laboratorios Farmaceuticos Rovi, S.A. | Composición farmacéutica con glicosaminoglicanos y su uso en tratamiento de úlceras crónicas |
US7799760B2 (en) | 2001-12-20 | 2010-09-21 | Centro De Ingenieria Genetica Y Biotecnologia | Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention |
WO2012101310A1 (es) | 2011-01-26 | 2012-08-02 | Laboratorios Farmacéuticos Rovi, S.A. | Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido nítrico, nitroderivados obtenidos y su uso en tratamiento de úlceras crónicas |
WO2014076336A1 (es) | 2012-11-13 | 2014-05-22 | Consejo Superior De Investigaciones Científicas (Csic) | Apósito para cicatrización de heridas comprometidas |
WO2018104874A1 (es) * | 2016-12-09 | 2018-06-14 | Desarrolladora Y Comercializadora De Tecnologías Biomédicas Decotecbio S.A.S. De C.V. | Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23529A1 (es) * | 2005-03-02 | 2010-06-17 | Ct Ingenieria Genetica Biotech | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
CU23526B6 (es) * | 2006-10-03 | 2010-05-19 | Ct Ingenieria Genetica Biotech | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
US8211947B2 (en) * | 2008-01-28 | 2012-07-03 | Guillermo Selman-Housein Sosa | Composition and method for treating and preventing musculoskeletal and connective tissue disorders |
CN101496486B (zh) * | 2009-03-13 | 2011-02-16 | 新疆巴音郭楞蒙古自治州农业科学研究所 | 一种蘑菇栽培方法 |
US9393177B2 (en) | 2013-08-20 | 2016-07-19 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
CN104173366A (zh) * | 2014-09-14 | 2014-12-03 | 陈钏黄 | 一种三磷酸腺苷二钠在制备治疗糖尿病足药物中的应用 |
WO2019006127A1 (en) * | 2017-06-28 | 2019-01-03 | Rutgers, The State University Of New Jersey | ORGANOIDS DERIVED FROM A SINGLE RENAL CELL |
WO2019006113A1 (en) * | 2017-06-28 | 2019-01-03 | Rutgers, The State University Of New Jersey | ORGANOIDS DERIVED FROM A SINGLE CEREBRAL CELL |
CU20190022A7 (es) * | 2019-03-18 | 2020-10-20 | Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma | Composición farmacéutica para el tratamiento de la úlcera del pie diabético |
WO2022060178A1 (ko) | 2020-09-21 | 2022-03-24 | 고려대학교 산학협력단 | 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법 |
KR102581240B1 (ko) | 2020-09-21 | 2023-09-22 | 고려대학교 산학협력단 | 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법 |
KR20230146379A (ko) | 2022-04-12 | 2023-10-19 | 고려대학교 산학협력단 | 마이크로바이옴을 이용하여 당뇨족부궤양 예후를 예측하는 방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0312208A1 (en) * | 1987-09-18 | 1989-04-19 | Ethicon, Inc. | Gel formulations containing growth factors |
WO1990001331A1 (en) * | 1988-08-10 | 1990-02-22 | Institute Of Molecular Biology, Inc. | Wound healing |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
US4944948A (en) | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
IL93996A0 (en) | 1989-04-04 | 1991-01-31 | Alcon Lab Inc | Pharmaceutical composition containing a liposome |
US5130298A (en) * | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
CA2038945A1 (en) | 1989-08-01 | 1991-02-02 | Norman D. Weiner | Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes |
AU629316B2 (en) | 1990-04-11 | 1992-10-01 | Flora Inc. | Periodontal disease treatment system |
CA2097063C (en) * | 1990-11-27 | 2006-08-08 | Howard P. Greisler | Tissue sealant and growth factor containing compositions that promote accelerated wound healing |
CN1160582A (zh) * | 1996-12-27 | 1997-10-01 | 暨南大学生物工程研究所 | 含有细胞生长因子的皮肤外用组合物 |
EP1305040B1 (en) * | 2000-07-28 | 2009-09-09 | Christopher J. Murphy | Transplant media |
HK1077740A1 (en) | 2001-12-20 | 2006-02-24 | Ct Ingenieria Genetica Biotech | Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation |
EP1482966B1 (en) | 2002-03-12 | 2014-05-14 | Bio-Click Technologies Ltd | Method and composition for treating skin wounds with epidermal growth factor |
CN1720989A (zh) | 2004-07-15 | 2006-01-18 | 深圳市清华源兴生物医药科技有限公司 | 一种表皮生长因子缓释微球及其制备方法与应用 |
-
2001
- 2001-12-04 HK HK05109793A patent/HK1077740A1/xx not_active IP Right Cessation
- 2001-12-20 CU CU20010308A patent/CU23043A1/es unknown
-
2002
- 2002-12-04 MX MXPA04005831A patent/MXPA04005831A/es active IP Right Grant
- 2002-12-04 BR BRPI0215214A patent/BRPI0215214B8/pt not_active IP Right Cessation
- 2002-12-04 AU AU2002361923A patent/AU2002361923B2/en not_active Expired
- 2002-12-04 US US10/499,457 patent/US7465704B2/en not_active Expired - Lifetime
- 2002-12-04 RU RU2004122091/15A patent/RU2289424C2/ru active
- 2002-12-04 DE DE60231248T patent/DE60231248D1/de not_active Expired - Lifetime
- 2002-12-04 EP EP02796491A patent/EP1466617B1/en not_active Expired - Lifetime
- 2002-12-04 UA UA20040705897A patent/UA80813C2/xx unknown
- 2002-12-04 SI SI200230818T patent/SI1466617T1/sl unknown
- 2002-12-04 CN CNB02828268XA patent/CN1306954C/zh not_active Expired - Lifetime
- 2002-12-04 KR KR1020047009772A patent/KR100795654B1/ko active IP Right Grant
- 2002-12-04 JP JP2003554215A patent/JP4808378B2/ja not_active Expired - Fee Related
- 2002-12-04 AT AT02796491T patent/ATE422897T1/de active
- 2002-12-04 WO PCT/CU2002/000011 patent/WO2003053458A1/es active IP Right Grant
- 2002-12-04 ES ES02796491T patent/ES2322568T3/es not_active Expired - Lifetime
- 2002-12-04 CA CA2470971A patent/CA2470971C/en not_active Expired - Lifetime
- 2002-12-04 DK DK02796491T patent/DK1466617T3/da active
- 2002-12-04 PT PT27964915T patent/PT1466617E/pt unknown
- 2002-12-13 AR ARP020104843A patent/AR037824A1/es active IP Right Grant
- 2002-12-18 MY MYPI20024760A patent/MY139214A/en unknown
-
2008
- 2008-08-22 US US12/197,001 patent/US7799760B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0312208A1 (en) * | 1987-09-18 | 1989-04-19 | Ethicon, Inc. | Gel formulations containing growth factors |
WO1990001331A1 (en) * | 1988-08-10 | 1990-02-22 | Institute Of Molecular Biology, Inc. | Wound healing |
Non-Patent Citations (4)
Title |
---|
BROWN G L ET AL: "Enhancement of epidermal regeneration by biosynthetic epidermal growth factor.", THE JOURNAL OF EXPERIMENTAL MEDICINE. UNITED STATES 1 MAY 1986, vol. 163, no. 5, 1 May 1986 (1986-05-01), pages 1319 - 1324, XP002238066, ISSN: 0022-1007 * |
BROWN G L ET AL: "Stimulation of healing of chronic wounds by epidermal growth factor.", PLASTIC AND RECONSTRUCTIVE SURGERY. UNITED STATES AUG 1991, vol. 88, no. 2, August 1991 (1991-08-01), pages 189 - 194, XP002238064, ISSN: 0032-1052 * |
HOGGE J ET AL: "The potential benefits of advanced therapeutic modalities in the treatment of diabetic foot wounds.", JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION. UNITED STATES FEB 2000, vol. 90, no. 2, February 2000 (2000-02-01), pages 57 - 65, XP002238065, ISSN: 8750-7315 * |
ZHU XIER ET AL: "Studies on enhancing the repair of gangrenous skin diabetic foot by epidermal growth factor.", NEW YORK 10159-2101, USA, no. 1141, 1997, 5th China-Japan Symposium on Diabetes Mellitus;Xian, China; September 5-8, 1996, Asia. 1997 Elsevier Science Publishers B.V.; Elsevier Science Publishing Co., Inc. PO Box 211, Sara Burgerhartstraat 25, pages 241 - 243, XP002238063, ISBN: 0-444-82664-5 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7799760B2 (en) | 2001-12-20 | 2010-09-21 | Centro De Ingenieria Genetica Y Biotecnologia | Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention |
WO2007073704A1 (es) | 2005-12-29 | 2007-07-05 | Centro De Ingeniería Genética Y Biotecnología | Uso tópico del factor de crecimiento epidermico en liposomas para prevenir la amputacion del pie diabético |
WO2007087759A2 (es) | 2006-01-31 | 2007-08-09 | Centro De Ingeniería Genética Y Biotecnología | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
WO2007087759A3 (es) * | 2006-01-31 | 2007-09-20 | Ct Ingenieria Genetica Biotech | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
AU2007211753B2 (en) * | 2006-01-31 | 2012-03-01 | Centro De Ingenieria Genetica Y Biotecnologia | Pharmaceutical composition of microspheres for preventing diabetic foot amputation |
US8741848B2 (en) | 2006-01-31 | 2014-06-03 | Centro De Ingenieria Genetica Y Biotecnologia | Pharmaceutical composition of microspheres for preventing diabetic foot amputation |
WO2010000904A1 (es) | 2008-07-01 | 2010-01-07 | Laboratorios Farmaceuticos Rovi, S.A. | Composición farmacéutica con glicosaminoglicanos y su uso en tratamiento de úlceras crónicas |
WO2012101310A1 (es) | 2011-01-26 | 2012-08-02 | Laboratorios Farmacéuticos Rovi, S.A. | Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido nítrico, nitroderivados obtenidos y su uso en tratamiento de úlceras crónicas |
WO2014076336A1 (es) | 2012-11-13 | 2014-05-22 | Consejo Superior De Investigaciones Científicas (Csic) | Apósito para cicatrización de heridas comprometidas |
WO2018104874A1 (es) * | 2016-12-09 | 2018-06-14 | Desarrolladora Y Comercializadora De Tecnologías Biomédicas Decotecbio S.A.S. De C.V. | Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos |
Also Published As
Publication number | Publication date |
---|---|
EP1466617A1 (en) | 2004-10-13 |
HK1077740A1 (en) | 2006-02-24 |
US20050107294A1 (en) | 2005-05-19 |
US20080312139A1 (en) | 2008-12-18 |
BRPI0215214B1 (pt) | 2017-05-30 |
MXPA04005831A (es) | 2004-09-13 |
RU2004122091A (ru) | 2005-04-10 |
US7465704B2 (en) | 2008-12-16 |
BRPI0215214B8 (pt) | 2021-05-25 |
RU2289424C2 (ru) | 2006-12-20 |
CN1620308A (zh) | 2005-05-25 |
JP4808378B2 (ja) | 2011-11-02 |
AR037824A1 (es) | 2004-12-09 |
CN1306954C (zh) | 2007-03-28 |
CU23043A1 (es) | 2005-05-20 |
DE60231248D1 (de) | 2009-04-02 |
SI1466617T1 (sl) | 2009-08-31 |
UA80813C2 (en) | 2007-11-12 |
PT1466617E (pt) | 2009-05-20 |
MY139214A (en) | 2009-08-28 |
KR100795654B1 (ko) | 2008-01-21 |
BR0215214A (pt) | 2004-12-07 |
ES2322568T3 (es) | 2009-06-23 |
CA2470971C (en) | 2011-02-01 |
AU2002361923A1 (en) | 2003-07-09 |
AU2002361923B2 (en) | 2006-02-02 |
EP1466617B1 (en) | 2009-02-18 |
JP2005516024A (ja) | 2005-06-02 |
ATE422897T1 (de) | 2009-03-15 |
US7799760B2 (en) | 2010-09-21 |
KR20040094669A (ko) | 2004-11-10 |
DK1466617T3 (da) | 2009-06-15 |
CA2470971A1 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003053458A1 (es) | Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético | |
ES2288024T3 (es) | Composiciones de hidrogel para la liberacion controlada en la administracion de factores de crecimiento. | |
JP3919212B2 (ja) | 線維障害の創傷治療処置 | |
AU2006268091B2 (en) | Promotion of epithelial regeneration | |
US20230372579A1 (en) | Methods for treating wounds | |
ES2475790T3 (es) | Composición oft�lmica basada en ácido lactobi�nico útil para reducir el edema de córnea e inflamación | |
ES2659437T3 (es) | Agente para tratar las cicatrices y el envejecimiento de la piel | |
CN107446018B (zh) | 促进伤口愈合的肽及其应用 | |
ES2210727T3 (es) | Composicion topica que contiene factor de crecimiento epidermico humano. | |
JP4096115B2 (ja) | 皮膚創傷治癒促進剤 | |
ES2227601T3 (es) | Uso de betaglicano para reducir la cicatrizacion. | |
ES2632164T3 (es) | Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea | |
JP2012012344A (ja) | 創傷治癒剤 | |
KR101110317B1 (ko) | 조직재생을 위한 티모신 베타-4 유래 Ac-SDKP 펩타이드의 스마트 방출지지체 | |
BRPI0507182B1 (pt) | uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados | |
ES2260634T3 (es) | Utilizacion de una sal de acido l-ascorbico para preparar una composicion farmaceutica para uso topico oftalmico capaz de mejorar el nivel de acido l-ascorbico del ojo. | |
ZA200405612B (en) | Use of a pharmaceutical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention | |
CN116999434A (zh) | HDAC5激活剂Gboxin在制备促进皮肤创面愈合的药物中的用途 | |
JP2023552515A (ja) | 創傷を治療するための組成物および方法 | |
ES2348471T3 (es) | Promotores de cicatrización de heridas. | |
ES2357601A1 (es) | Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido nítrico y su uso en tratamiento de úlceras crónicas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 295/MUMNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/005831 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2470971 Country of ref document: CA Ref document number: 2003554215 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047009772 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200405612 Country of ref document: ZA Ref document number: 2004/05612 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002796491 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004122091 Country of ref document: RU Ref document number: 2002361923 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002828268X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002796491 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10499457 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002361923 Country of ref document: AU |